123results about "Protozoa material medical ingredients" patented technology

Storage stable compositions of biological materials, including bioactive biological materials are provided in the form of a water-in-oil emulsion, comprising:(a) cellular material selected from living and / or dormant prokaryotic and / or eukaryotic cells and tissues, the cellular material being compatible with water-in-oil emulsions;(b) one or more oils selected from vegetable oils and fish oils;(c) an oil-soluble nonionic polymeric surfactant having a molecular weight of from about 2500 to about 15000; and(d) water.The compositions may also contain a thickener such as a hydrophobic fumed silica or bentonite.Compositions may be used for various purposes, depending on the contained biological material. Specific examples include compositions containing Fusarium lateritium control of Eutypa lata in plant wounds made by cutting or pruning, and compositions containing Lagenidium giganteum for control of mosquitoes.

The present invention features a unique, natural formulation and method of administering the same to treat and prevent diabetes, or rather advances treatment of diabetes, by providing a naturaceutical composition or treatment formulated with one or more processed Morinda citrifolia products as derived from the Indian Mulberry plant. The Morinda citrifolia is particularly adapted to treat Type II diabetes. The Morinda citrifolia product is preferably a leaf extract, but may also be in the form of a juice, a puree juice, a dietary fiber, or other similar forms and is incorporated into various carriers or naturaceutical compositions suitable for in vivo treatment of a patient. The naturaceutical may also combine other food products into the naturaceutical, such as fruit juices, dietary supplements, vitamins and minerals, and others.

The present invention is directed to isolated Bacillus subtilis, Pseudomonas putida, and Sporobolomyces roseus which are useful as a biocontrol agent. These organisms are useful in a method of imparting to plants protection against plant pathogens by applying them to plants, plant seeds, or soil surrounding plants under conditions effective to impart disease protection to the plants or plants produced from the plant seeds. The biocontrol agents are also useful in a method of enhancing plant growth which involves applying them to plants, plants seeds, or soil surrounding plants under conditions effective to enhance growth in the plants or plants produced from the plant seeds.

Infant formula compositions containing docosapentaenoic acid n-6 (“DPA(n-6)”) and other polyunsaturated fatty acids and methods for their preparation and use are provided.

Devices, methods, and systems are described for administration to at least one biological tissue of at least one device including at least one altered microorganism. In an embodiment, the altered microorganism includes at least one nucleic acid construct encoding at least one therapeutic agent.

The present invention relates to a kind of smoking-stopping health inhalant and its making process. The smoking-stopping health inhalant is one kind of cigarette made of shredded health Chinese medicinal material and with inner or outer nicotine. Its Chinese medicinal material includes chrysanthemum 40%-70%, plantain 5%-10%, mint leaf 10%-29%, honeysuckle 5-10%, ginkgo leaf 5%-10% and licorice 1%-5%. Its nicotine content is reduced gradually, so that the smoker can give up smoking gradually through eliminating the dependence on nicotine.

Differentially expressed Leishmania genes and proteins are described. One differentially expressed gene (A2) is expressed at significantly elevated levels (more than about 10 fold higher) in the amastigote stage of the life cycle when the Leishmania organism is present in macrophages than in the free promastigote stage. The A2 gene encodes a 22 kD protein (A2 protein) that is recognized by kala-azar convalescent serum and has amino acid sequence homology with an S-antigen of Plasmodium falcilparum Vietnamese isolate VI. Differentially expressed Leishmania genes and proteins have utility as vaccines, diagnostic reagents, as tools for the generation of immunological reagents and the generation of attenuated variants of Leishmania.

The present invention features a unique, natural formulation and method of administering the same to treat and prevent diabetes, or rather advances treatment of diabetes, by providing a naturaceutical composition or treatment formulated with one or more processed Morinda citrifolia products as derived from the Indian Mulberry plant. The Morinda citrifolia is particularly adapted to treat Type II diabetes. The Morinda citrifolia product is preferably a leaf extract, but may also be in the form of a juice, a puree juice, a dietary fiber, or other similar forms and is incorporated into various carriers or naturaceutical compositions suitable for in vivo treatment of a patient. The naturaceutical may also combine other food products into the naturaceutical, such as fruit juices, dietary supplements, vitamins and minerals, and others.

There is now a market for kits containing the necessary components for performing protein synthesis reactions using template DNA of the experimenter. One category of existing system for performing protein synthesis reactions is based on an S-30 extract from the bacteria E. coli. It is disclosed here that a simple fractionation process can dramatically improve the performance of an S-30 prokaryotic protein synthesis reaction mixture. In one embodiment, the fractionation is a simple freezing and thawing of an S-30 extract combined with a supplemental mix, followed by centrifugation. The resulting fractionated S-30 reaction mixture yields more full-length target protein and less non-full length or non-target protein than possible using prior art S-30 systems.

The invention relates to the effective parts of rosemary, its preparation method and use, wherein the effective parts of the Rosmarinus officinalisl are diterpenoids phenols extracted from medicinal material of Rosmarinus officinalisl, the content of the phenols is over 45%, and the sum of the content of the carnosol and carnosic acid as the principal ingredients is over 13%. The preparing process comprises curing the Rosmarinus officinalisl medicinal material and cutting it into chunks, charging raffinate for extraction, cooling down the merged extract and filtrating, decolorizing with activated charcoal, concentrating the filtrate and charging in water, filtering, drying and disintegrating the filtering deposit. The effective parts of the Rosmarinus officinalisl can be used for preparing medicament for preventing and treating cardiovascular diseases, epigastric pain, uterocarcinoma, cervical carcinoma, intestinal cancer and breast cancer.

The present invention is directed to isolated Bacillus subtilis, Pseudomonas putida, and Sporobolomyces roseus which are useful as a biocontrol agent. These organisms are useful in a method of imparting to plants protection against plant pathogens by applying them to plants, plant seeds, or soil surrounding plants under conditions effective to impart disease protection to the plants or plants produced from the plant seeds. The biocontrol agents are also useful in a method of enhancing plant growth which involves applying them to plants, plants seeds, or soil surrounding plants under conditions effective to enhance growth in the plants or plants produced from the plant seeds.

The present invention provides a particle comprising a polypeptide and at least one malaria antigen, and a composition or vaccine comprising thereof, its use in medicine, particularly in the prevention or treatment of malaria infections.

Disclosed are apparatuses and methods for the production of attenuated aseptic parasites in haematophagous insects generally, and production of Plasmodium species sporozoites in Anopheles species mosquitoes specifically; apparatuses and methods for the production of strains of haematophagous insects with desired properties such as hypoallergenicity or hyperinfectivity; methods of producing a parasite strain that is capable of withstanding cyropreservation at temperatures close to freezing; apparatuses and methods for the injection of an attenuated parasite vaccine; production of parasites and haematophagous insects that are free from contamination by unwanted biological agents; apparatuses for the reconstruction of complex parasitic life cycles aseptically to avoid the contamination of the parasite or the insect vector host with unwanted biological agents.

Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to four biotinylated components, and further wherein at least two of the four biotinylated components are not identical.

The invention relates to T. cruzi trans-sialidase (TS) and to the neurotrophic and IL-6 secretion-inducing activities of the protein. TS, neurotrophic variants and / or neurotrophic peptides based upon the sequence of TS can be administered to a mammal to directly or indirectly provide neurotrophic support for neurons. A mammalian neurotrophic factor (e.g., CNTF, LIF) can be co-administered with the TS, neurotrophic variant and / or neurotrophic peptide. TS, IL-6 secretion-inducing variants and / or IL-6 secretion-inducing peptides based upon the sequence of TS can be administered to a mammal to induce the secretion of IL-6. TS, active variants and / or active peptides can be administered to a mammal having an acquired or congenital condition characterized by neuronal degeneration or to a mammal that has experienced trauma to the brain, spinal cord or peripheral nerves. The invention also relates to neurotrophic and IL-6 secretion-inducing variants of TS and to neurotrophic and IL-6 secretion-inducing peptides. The invention also relates to compositions comprising TS, active variants thereof and / or active peptides and a physiologically acceptable carrier.

The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., a lantibiotic-based spore decontaminant (e.g., comprising nisin)) and methods of neutralizing (e.g., killing or inhibiting growth or inhibiting germination of) bacteria (e.g., cells and spores). For example, the present invention provides nisin-based compounds (e.g., for bacterial spore decontamination) and methods of using the same in research, therapeutic and drug screening applications.

The present invention provides a particle comprising a polypeptide and at least one malaria antigen, and a composition or vaccine comprising thereof, its use in medicine, particularly in the prevention or treatment of malaria infections.

The present invention provides a novel use of coccidian, specifically relates to the use of coccidian as a vaccine live vector. The present invention further provides a live vaccine with coccidian as a vector, which is transgenic coccidian capable of expressing exogenous protein or stably transfected coccidian that contain expression vector and can express exogenous coccidian. The present coccidian vector live vaccine can induce organisms to simultaneously generate protective humoral and cellular immune responses (including the mucosal immune response), as well as generate memory responses, which can be readily carried out and has stable effect and high biological safety without generating immune tolerance.

The present invention provides cell free preparations of protozoan microsomes, wherein the cell free preparation of protozoan microsomes demonstrate the ability to translocate a protozoan polypeptide into the microsome, methods of preparing cell free preparations of protozoan microsomes, and methods of using cell free preparations of protozoan microsomes.

The present invention provides a protein having an A chain of a ricin-like toxin, a B chain of a ricin-like toxin and a heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a disease specific protease such as a cancer, fungal, viral or parasitic protease. The invention also relates to a nucleic acid molecule encoding the protein and to expression vectors incorporating the nucleic acid molecule. Also provided is a method of inhibiting or destroying mammalian cancer cells, cells infected with a virus, a fungus, or parasite; or parasites utilizing the nucleic acid molecules and proteins of the invention and pharmaceutical compositions for treating human cancer, viral infection, fungal infection, or parasitic infection.

The present invention relates to the field of treatment of tumor, and especially to a composition comprising a plasmodium, a treatment method and an application thereof. The composition of the present invention has therapeutic effects on colorectal carcinoma, lung carcinoma, breast carcinoma, gastric carcinoma and hepatic carcinoma etc., can inhibit the growth of tumor and prolong the life of the tumor patients, whereas has no therapeutic effect on melanoma and lymphoma; meanwhile, the present invention describes that the long-term plasmodium infection has better therapeutic effect on tumors, and the plasmodium immunotherapy of the present invention does not take the fever time as a course standard when treating tumors, but should be used to extend the duration of plasmodium infection as much as possible until the progression of tumors can be controlled under the premise of protecting the organ functions and life safety of the patients.

The invention relates to a fusion gene for expressing Fc fragment of chicken IgY molecules and avian influenza virus antigen and an application of the same. The fusion gene is constructed by means of an HA1 gene fragment of avian influenza virus H9N2 sub-type and the Fc gene fragment of the chicken IgY molecule and then is transfected to eimeria mitis to obtain transgenic coccidium. The transgenic coccidium is inoculated through an oral method for enhance immune reaction aiming to an avian influenza specific antigen in chickens. The application is simple to carry out, is low in cost and has an excellent application prospect.

The present invention relates to a process for producing arachidonic acid. In one embodiment, Mortierella sect. schmuckeri microorganisms are cultured in fermentation medium, preferably containing a component of a complex nitrogen source. Further disclosed is a food product which includes Mortierella sect. schmuckeri microorganisms or lipid isolated from such microorganisms to enhance the arachidonic acid content of the food product.

The invention relates to T. cruzi trans-sialidase (TS) and to the neurotrophic and IL-6 secretion-inducing activities of the protein. TS, neurotrophic variants and / or neurotrophic peptides based upon the sequence of TS can be administered to a mammal to directly or indirectly provide neurotrophic support for neurons. A mammalian neurotrophic factor (e.g., CNTF, LIF) can be co-administered with the TS, neurotrophic variant and / or neurotrophic peptide. TS, IL-6 secretion-inducing variants and / or IL-6 secretion-inducing peptides based upon the sequence of TS can be administered to a mammal to induce the secretion of IL-6. TS, active variants and / or active peptides can be administered to a mammal having an acquired or congenital condition characterized by neuronal degeneration or to a mammal that has experienced trauma to the brain, spinal cord or peripheral nerves. The invention also relates to neurotrophic and IL-6 secretion-inducing variants of TS and to neurotrophic and IL-6 secretion-inducing peptides. The invention also relates to compositions comprising TS, active variants thereof and / or active peptides and a physiologically acceptable carrier.

The invention relates to T. cruzi trans-sialidase (TS) and to the neurotrophic and IL-6 secretion-inducing activities of the protein. TS, neurotrophic variants and / or neurotrophic peptides based upon the sequence of TS can be administered to a mammal to directly or indirectly provide neurotrophic support for neurons. A mammalian neurotrophic factor (e.g., CNTF, LIF) can be co-administered with the TS, neurotrophic variant and / or neurotrophic peptide. TS, IL-6 secretion-inducing variants and / or IL-6 secretion-inducing peptides based upon the sequence of TS can be administered to a mammal to induce the secretion of IL-6. TS, active variants and / or active peptides can be administered to a mammal having an acquired or congenital condition characterized by neuronal degeneration or to a mammal that has experienced trauma to the brain, spinal cord or peripheral nerves. The invention also relates to neurotrophic and IL-6 secretion-inducing variants of TS and to neurotrophic and IL-6 secretion-inducing peptides. The invention also relates to compositions comprising TS, active variants thereof and / or active peptides and a physiologically acceptable carrier.